For: | Soldera J. Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis. World J Clin Cases 2024; 12(24): 5468-5472 [PMID: 39188602 DOI: 10.12998/wjcc.v12.i24.5468] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v12/i24/5468.htm |
Number | Citing Articles |
1 |
Tugrul Purnak, Atilla Ertan. Optimal Management of Patients with Moderate-to-Severe Inflammatory Bowel Disease. Journal of Clinical Medicine 2024; 13(23): 7026 doi: 10.3390/jcm13237026
|
2 |
Maryia Zhdanava, Sabree Burbage, Todor I. Totev, Sumesh Kachroo, Lilian Diaz, Bridget Godwin, Patrick Lefebvre, Dominic Pilon. Real-world prevalence of potential drug–drug interactions associated with oral advanced therapies indicated for ulcerative colitis. Current Medical Research and Opinion 2025; : 1 doi: 10.1080/03007995.2025.2465649
|
3 |
Ming-Jung Meng, Chia-Jung Kuo, Ming-Wei Lai, Cheng-Tang Chiu, Ming-Yao Su, Ming-Ling Chang, Puo-Hsien Le. Advanced Combination Therapy with Biologics and Upadacitinib in Refractory Inflammatory Bowel Disease: A Retrospective Study from Taiwan. Journal of Inflammation Research 2025; : 2733 doi: 10.2147/JIR.S511309
|
4 |
|